BRIEF published on 01/29/2025 at 08:05, 1 year 9 months ago TME Pharma and aimed analytics: Innovative partnership for drug discovery through AI Biotechnology Artificial Intelligence Partnership Cancer Drugs
PRESS RELEASE published on 01/29/2025 at 08:00, 1 year 9 months ago Inside Information / Other news releases TME Pharma collaborates with aimed analytics for AI-driven drug discovery, strengthening capabilities for strategic transactions. The partnership utilizes AI to accelerate drug development and optimize existing therapies Strategic Partnerships Cancer Treatment TME Pharma AI-driven Drug Discovery Aimed Analytics
BRIEF published on 12/23/2024 at 21:09, 1 year 10 months ago Successful public offering of TME Pharma NV Shareholders Capital Increase Cancer Financial Strategies NOX-A12
BRIEF published on 12/04/2024 at 19:55, 1 year 11 months ago TME Pharma Announces Strategic Update and €2.6 Million Financing Plan Public Offer Corporate Strategy Financing Plan NOX-A12 Development Shareholder Priority
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 11 months ago Inside Information / Other news releases TME Pharma announces corporate strategy update with upcoming €2.6 million financing aimed at further developing therapies for cancer treatment through public offer open to shareholders. CEO Mangasarian highlights strategic goals and plans Financing Cancer Treatment Public Offer Corporate Strategy TME Pharma
BRIEF published on 11/23/2024 at 10:59, 1 year 11 months ago TME Pharma Presents Findings on NOX-A12 in Glioblastoma Cancer Therapy Glioblastoma NOX-A12 Immune Checkpoint Inhibition Tumor Microenvironment
PRESS RELEASE published on 11/23/2024 at 10:54, 1 year 11 months ago Inside Information / Other news releases TME Pharma presents poster on NOX-A12 inhibition of CXCL12 in glioblastoma at 2024 SNO Annual Meeting, demonstrating enhanced anti-tumor immune responses in brain cancer models Glioblastoma TME Pharma NOX-A12 CXCL12 Inhibition SNO Annual Meeting
BRIEF published on 08/12/2024 at 19:05, 2 years 2 months ago TME Pharma Increases Allocated Resources for Liquidity Contract Liquidity Contract INVEST SECURITIES AMF Decision TME Pharma Share Allocation
PRESS RELEASE published on 08/12/2024 at 19:00, 2 years 2 months ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract TME Pharma increases resources for liquidity contract with Invest Securities to support cash balance and securities. Details of the update provided in accordance with AMF regulations Liquidity Contract Biotechnology INVEST SECURITIES AMF Regulations TME Pharma
Published on 11/06/2026 at 05:15, 6 hours 8 minutes ago Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins
Published on 11/06/2026 at 00:53, 10 hours 30 minutes ago Sekur Private Data Engages Darkstar Capital for Investor Awareness and Sekur Product Distribution
Published on 11/06/2026 at 00:45, 10 hours 38 minutes ago Gabriel Announces Closure of ICSID Annulment Proceedings
Published on 11/06/2026 at 10:28, 54 minutes ago Tradegate BSX continues to expand its reach in the German retail investor market
Published on 11/06/2026 at 10:15, 1 hour 7 minutes ago Marco Fuchs Receives EY Entrepreneur Of The Year 2026 Award
Published on 11/06/2026 at 10:05, 1 hour 17 minutes ago Smart City Expo 2026 closes after showing the real impact of urban solutions
Published on 11/06/2026 at 09:58, 1 hour 24 minutes ago EQS-Adhoc: Uniper SE establishes dividend policy
Published on 11/06/2026 at 09:42, 1 hour 40 minutes ago Silver for the Thorium Pioneer: Emerald Horizon Takes Second Place at “Innovator of the Year” 2026
Published on 11/05/2026 at 18:21, 17 hours 1 minute ago Total number of voting rights and shares making up the share capital at October 31, 2026
Published on 11/05/2026 at 17:45, 17 hours 38 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 11/05/2026 at 17:29, 17 hours 53 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN FR0010406082
